Check patentability & draft patents in minutes with Patsnap Eureka AI!

Administration of the reg1 anticoagulation system

A technology of drug delivery and anticoagulant, which is applied in the field of drug delivery of REG1 anticoagulant system, can solve the problem of not supporting the persistence in the body, the antibody does not show anticoagulant or other pharmacological activities, and the production of thrombin is reduced or eliminated And other issues

Inactive Publication Date: 2009-06-10
REGADO BIOSCI
View PDF28 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Second, inhibition or loss of FIXa activity will have profound effects on the reproductive phase of blood coagulation, leading to a significant reduction or elimination of thrombin production
The 2'-O-methyl modification conferred modest nuclease resistance to the antidote, which provided sufficient in vivo stability to seek and bind RB006, but did not support prolonged in vivo persistence
Furthermore, the antibody did not exhibit any anticoagulant or other pharmacological activity in vitro in human plasma or in animals following intravenous bolus administration

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Administration of the reg1 anticoagulation system
  • Administration of the reg1 anticoagulation system
  • Administration of the reg1 anticoagulation system

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0138] Tests for blood clotting measures

[0139] Standard measurements of blood coagulation include the plasma-based prothrombin time (PT) and activated partial thromboplastin time (APTT) assays, both in plasma and whole blood, and the whole blood-based activated clotting time (ACT ) to measure. Although the activators used to initiate blood coagulation differ in each of these assays, a feature they all share is clot formation as the assay endpoint. Importantly, in these in vitro assays, low levels of thrombin ~10-30 nM were sufficient to generate sufficient fibrin to reach the endpoint. This thrombin level represents a conversion rate of only 3-5% from prothrombin to thrombin and is consistent with the amount of thrombin produced during the initial phase of the clotting reaction (Butenas et al., 2003; Mann et al., 2003). Thus, these assays generally report the initial phase of the coagulation reaction and do not adequately reflect the absence or inhibition of coagulation...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An improved method of administration of an aptamer and antidote system to regulate blood coagulation in a host is provided based on weight adjusted or body mass index-adjusted dosing of the components of the system to provide a desired pharmacodynamic response. In addition, a method of reversing activity of the aptamer to a desired extent is provided where an antidote dose is based solely on its relationship to the aptamer dose.

Description

[0001] Cross References to Related Applications [0002] This application requires U.S. Provisional Application No. 60 / 808,987 filed May 26, 2006, both titled "Administration of the REG1 Anticoagulant System"; U.S. Provisional Application No. 60 / 847,809 and priority to US Provisional Application No. 60 / 865,352, filed November 10, 2006, the entire disclosure of which is incorporated herein by reference. field of invention [0003] An improved method of administering an aptamer and antidote system to control blood coagulation in a host is provided based on body weight-adjusted or body mass index-adjusted dosing of components of the system. Background of the invention [0004] emergency care anticoagulation [0005] Given the central role of injectable anticoagulants for thrombosis in the pathology of acute ischemic heart disease, injectable anticoagulants have become an important factor in patients with acute coronary syndromes such as unstable angina and myocardial infarct...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A01N43/04A61K31/70A61K38/00A61K31/715C12N15/00
CPCA61K31/00A61K49/00A61P39/02A61P7/02A61K48/00
Inventor C·P·拉斯科尼R·M·通肯斯
Owner REGADO BIOSCI
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com